港股詳情

本页面由TTMF Limited提供服务

邁威生物-B待上市

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：4.00億

香港流通股本：4.00億

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

市銷率: - -

1

开始申购

04/20

2

申購截止

04/23 10:15

3

公布中签

04/24

4

暗盘

04/27 16:15 - 18:30

5

挂牌上市

04/28

總覽公司新聞資訊公告

新股孖展統計 | 4月20日

卡位ADC、TCE前沿賽道，邁威生物(02493)港股IPO含金量有幾分？

新股招股 | 邁威生物-B今起招股至4月23日招股，一手入場費6203.95港元，引入君實生物、桂林三金及藥明生物等基石投資者

老虎资讯综合

邁威生物-B(02493)今起招股君實生物、桂林三金及藥明生物等基石認購5300萬美元發售股份

新股消息：專注腫瘤與年齡相關疾病的製藥企業全球發售4,713.02萬股H股，最高發售價每股30.71港元

邁威生物「A+H」雙平台啓航：ADC尖刀出鞘，平台優勢鑄就底色

9年燒了52億，邁威生物還在給創新藥「交學費」

邁威生物通過上市聆訊：2025年營收6.6億虧損9.7億

新股消息 | 邁威生物(688062.SH)通過港交所聆訊兩年累計虧損超20億元

營收狂飆230%卻負重前行！邁威生物攜ADC「利刃」二次叩關港交所|港E聲

新股消息 | 邁威生物(688062.SH)二次遞表港交所已有三款商業化的生物類似藥產品

新股消息 | 邁威生物(688062.SH)二次遞表港交所

邁威生物(688062.SH)發布2025年度業績，歸母淨虧損9.69億

超10家赴港排隊上市，「A+H」成醫藥IPO新選擇，A股藥企為何集體奔赴港股？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02493/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02493","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"邁威生物-B","latestPrice":0,"timestamp":1776672000000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":400000000,"shares":400000000,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"04-20 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":8,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1776648600000,1776657600000],[1776661200000,1776672000000]],"volumeRatio":0,"ipoDetail":{"name":"迈威生物－Ｂ","exchange":"SEHK","listingDate":"2026-04-28","sharesOutstanding":446730200,"sharesFloat":446730200,"offerAmount":47130200,"priceRange":"27.640 - 30.710","market":"HK","openProspectusDate":"2026-04-20","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0420/2026042000012_c.pdf","purchaseBeginDate":"2026-04-20","purchaseEndDate":"2026-04-23","winningDate":"2026-04-27","currency":"HKD","minPurchaseQuantity":200,"peRate":-12.17,"use":"1、约56.8%，或713.0百万港元将用于核心产品9MW2821针对多种适用症不同阶段的临床开发试验；\n2、约17.7%，或222.3百万港元将用于针对具有大量临床需求的肿瘤和年龄相关疾病的其他管线产品的研发；\n3、约15.5%，或194.7百万港元将用于商业化目的；\n4、约10.0%，或125.6百万港元将用于营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司成立于2017年，是一家以药物研发方面的创新能力以及从药物发现至商业化销售的端到端能力而闻名的中国制药公司。公司主要专注于自主开发肿瘤、免疫、眼科、骨科等领域的药物。公司建立了管线产品组合，包括10个以上不同品种的药物资产，包括一款自研核心产品9MW2821（bulumtatug fuvedotin （「BFv」），靶向Nectin-4的ADC候选药物）。","subscribed":19.83,"marketCap":12348000000,"minimumCapital":6203.95,"overAllotment":false,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,2000000,2356600","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-04-27","greyDateTimestamp":1777219200000,"greyOpeningTime":1777277700000,"greyClosingTime":1777285800000,"showGreyQuote":false,"openProspectusDate":"2026-04-20","listingDate":"2026-04-28"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","floatShares":400000000,"roa":"--","roe":"--","lyrEps":0,"shares":400000000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02493\",,undefined,":{"id":9896,"type":"COMMON","ipoName":"02493-IPO","symbol":"02493","companyName":"邁威生物-B","market":"HK","currency":"HKD","status":"OPEN","underwriter":"中信證券(香港)有限公司","lotSize":200,"minQty":200,"expectedOfferingSize":47130200,"openingDate":1776648600000,"closingDate":1776910500000,"commonClosingDate":1776910500000,"allotmentDate":1776960000000,"listDate":1777305600000,"marginable":true,"marginRate":10,"latestPrice":30.71,"minPrice":27.64,"maxPrice":30.71,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0420/2026042000012_c.pdf","allowedQuantities":[200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,2000000,2356600],"interestRate":0,"recommend":false,"isHint":false,"interestStartDate":1776873600000,"interestEndDate":1776873600000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1777277700000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[{"ipoName":"02493-IPO","ipoId":9896,"financingId":59183,"type":1,"availableFundLimit":6203.94,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":62039.4,"maxSubscribeLimit":-1,"marginRate":10,"interestRate":0,"openTime":1776648600000,"closeTime":1776910500000,"isAtValidTime":true,"subscriptionMethod":"FINANCING","processFee":0,"supportPI":false,"applyFundLimit":6203.94,"threshold":50000000000,"isAvailable":false},{"ipoName":"02493-IPO","ipoId":9896,"financingId":59176,"type":4,"availableFundLimit":6203.94,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":0,"maxSubscribeLimit":-1,"marginRate":100,"interestRate":0,"openTime":1776648600000,"closeTime":1776910500000,"isAtValidTime":true,"subscriptionMethod":"CASH","processFee":0,"supportPI":false,"applyFundLimit":6203.94,"threshold":50000000000,"isAvailable":false}],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[{"method":"FINANCING","closeTime":1776910500000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":6203.94},{"method":"CASH","closeTime":1776910500000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":6203.94}],"latestClosingDate":1776910500000,"subscribedFinanceRatio":19.83,"subscribedRatio":19.83,"forecastRatio":28.75,"raiseMoney":144740000,"totalMargin":2870590000,"quoteInfoUpdatedAt":1776706488788,"forecastMarketValue":13033353585,"minForecastMarketValue":12347622728,"maxForecastMarketValue":13719084442,"sharesOutstanding":446730200,"business":"公司成立於2017年，是一家以藥物研發方面的創新能力以及從藥物發現至商業化銷售的端到端能力而聞名的中國製藥公司。公司主要專註於自主開發腫瘤、免疫、眼科、骨科等領域的藥物。公司建立了管線產品組合，包括10個以上不同品種的藥物資產，包括一款自研核心產品9MW2821（bulumtatug fuvedotin （「BFv」），靶向Nectin-4的ADC候選藥物）。","greyOpeningTime":1777277700000,"greyClosingTime":1777285800000,"tradable":true,"showClawback":true,"clawbackType":"機制B","clawbackRate":10},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02493\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628742484","title":"新股孖展統計 | 4月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742484?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 18:54","pubTimestamp":1776682483,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华勤技术(03296)、曦智科技(01879)、迈威生物(02493)正在招股中。截至4月20日，富途证券、辉立证券等券商为华勤技术借出1917.21亿港元，超购逾421.43倍；为曦智科技借出458.8亿港元，超购逾363.07倍；为迈威生物借出26.23亿港元，超购逾18.11倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01879","03296","02493","BK1193"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628790385","title":"卡位ADC、TCE前沿賽道，邁威生物(02493)港股IPO含金量有幾分？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628790385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628790385?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 09:40","pubTimestamp":1776649207,"startTime":"0","endTime":"0","summary":"2026年4月20日，迈威生物正式启动招股程序，中信证券与海通国际担任联席保荐人。在这一波创新药出海浪潮中，手握全球领先管线的迈威生物无疑将受到市场密切关注。通过ADC与TCE双平台驱动，叠加多元化的创新管线布局，迈威生物正在肿瘤治疗领域构建起差异化的强大竞争壁垒。从业绩来看，迈威生物已交出了一份颇具说服力的答卷：2024-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","688062","BK4588","VXUS","02493","BK4080","ADC","BK0239","BK4585","BK4231","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151703007","title":"新股招股 | 邁威生物-B今起招股至4月23日招股，一手入場費6203.95港元，引入君實生物、桂林三金及藥明生物等基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=1151703007","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151703007?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 07:57","pubTimestamp":1776643056,"startTime":"0","endTime":"0","summary":"$迈威生物-B$ 今日至4月23日招股，公司拟全球发售4713.02万股H股，香港公开发售占10%，国际发售占90%。每股发售价27.64-30.71港元，每手200股，一手入场费6203.95港元，预期H股将于香港时间2026年4月28日(星期二)上午九时正开始在联交所买卖。2025年8月，迈利舒及迈卫健获巴基斯坦药品监管局上市批准。于2024年及2025年，净亏损分别为约10.47亿元及9.72亿元，主要由于研发活动所产生的成本及开支。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7550d94007d2725194e03b33a683be79","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7550d94007d2725194e03b33a683be79"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799412","title":"邁威生物-B(02493)今起招股 君實生物、桂林三金及藥明生物等基石認購5300萬美元發售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628799412?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 06:34","pubTimestamp":1776638067,"startTime":"0","endTime":"0","summary":"2025年8月，迈利舒及迈卫健获巴基斯坦药品监管局上市批准。迈利舒及迈卫健是在巴基斯坦获批的首个Prolia及Xgeva生物类似药。于2024年及2025年，净亏损分别为约10.47亿元及9.72亿元，主要由于研发活动所产生的成本及开支。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","688180","LU0140636845.USD","BK1161","LU0043850808.USD","LU0181495838.USD","02269","LU0417516738.SGD","BK0060","LU0588546209.SGD","BK1583","LU0516423091.SGD","LU0516422366.SGD","LU0039217434.USD","LU0979878070.USD","LU0417516902.SGD","LU0052750758.USD","LU2039709279.SGD","LU0823426480.USD","SG9999002562.SGD","LU0326950275.SGD","LU1720050803.USD","LU0572944931.SGD","LU0819121731.USD","LU0516422440.USD","688062","LU0456827905.SGD","BK1589","LU0456846285.SGD","LU0327786744.USD","BK0239","002275","BK0188","LU0823426308.USD","LU1880383366.USD","BK1576","LU0856984785.SGD","BK0028","BK1515","LU3063872942.SGD","LU0051755006.USD","LU1794554557.SGD","01877","LU0307460666.USD","LU0516423174.USD","LU1242518857.USD","SG9999002463.SGD","BK1610","LU0348735423.USD","LU1688375341.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181992482","title":"新股消息：專注腫瘤與年齡相關疾病的製藥企業全球發售4,713.02萬股H股，最高發售價每股30.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181992482","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181992482?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 06:26","pubTimestamp":1776637606,"startTime":"0","endTime":"0","summary":"同时，公司也在自体免疫性疾病及其他相关药物方面进行研发布局，形成多款在研产品与上市产品并行的管线。全球肿瘤药物市场近年来保持快速增长，受人口老龄化、疾病谱转变及创新疗法不断涌现的驱动，市场规模从2019年的约1,435亿美元增长势头强劲。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2627747642","title":"邁威生物「A+H」雙平台啓航：ADC尖刀出鞘，平台優勢鑄就底色","url":"https://stock-news.laohu8.com/highlight/detail?id=2627747642","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627747642?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 09:24","pubTimestamp":1776216266,"startTime":"0","endTime":"0","summary":"随着核心品种关键临床节点密集兑现、全球化布局稳步落地，这家年轻的中国创新药企，正以ADC为利刃，借政策与资本东风，在全球肿瘤创新药赛场，奏响中国药企突围进阶的时代强音。","market":"hk","thumbnail":"https://img2.gelonghui.com/b9ad4-4ef65188-5c75-45f1-aeaa-9221d6b4720f.jpg?guru_height=852&guru_width=1280&guru_size=143965","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b9ad4-4ef65188-5c75-45f1-aeaa-9221d6b4720f.jpg?guru_height=852&guru_width=1280&guru_size=143965"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4411775","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["688062","BK4080","BK4231","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626964138","title":"9年燒了52億，邁威生物還在給創新藥「交學費」","url":"https://stock-news.laohu8.com/highlight/detail?id=2626964138","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626964138?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 21:51","pubTimestamp":1775742711,"startTime":"0","endTime":"0","summary":"2025年1月，迈威生物首次向港交所递交招股书，此后经历失效、再递表，直至近期通过聆讯。回望2022年初，迈威生物登陆科创板，募集资金净额约33亿元。迈威生物已上市的产品，面临的共同困境是“上市即红海”。然而，迈威生物的核心产品君迈康在2023年获批上市时，其所在的靶点领域早已是多家竞品激烈角逐的红海。招股书中，迈威生物也明确了“候选药物可能未能成功通过临床开发或未能获得监管批准”这一风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775644767954541046","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","688062","02493","BK1574","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624318106","title":"邁威生物通過上市聆訊：2025年營收6.6億 虧損9.7億","url":"https://stock-news.laohu8.com/highlight/detail?id=2624318106","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624318106?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 09:49","pubTimestamp":1775180975,"startTime":"0","endTime":"0","summary":"迈威(上海)生物科技股份有限公司（简称：“迈威生物”）日前通过上市聆讯，准备在港交所上市。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391080655019962617135090.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260403/6391080655019962617135090.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33177/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633710","title":"新股消息 | 邁威生物(688062.SH)通過港交所聆訊 兩年累計虧損超20億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633710","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624633710?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 07:48","pubTimestamp":1775173712,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513062","title":"營收狂飆230%卻負重前行！邁威生物攜ADC「利刃」二次叩關港交所|港E聲","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513062","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513062?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 20:12","pubTimestamp":1775045542,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tfcaijing.com/article/page/3433344530792b49374c58684d3248752f3831627a673d3d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622883853","title":"新股消息 | 邁威生物(688062.SH)二次遞表港交所 已有三款商業化的生物類似藥產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883853","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883853?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 06:55","pubTimestamp":1774479330,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071230","title":"新股消息 | 邁威生物(688062.SH)二次遞表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071230","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071230?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:45","pubTimestamp":1774446320,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所3月25日披露，迈威(上海)生物科技股份有限公司(迈威生物(688062.SH))向港交所主板递交上市申请书，中信证券和海通国际为联席保荐人。这是该公司第二次递表港交所。据招股书，迈威生物的核心产品9MW2821是一款靶向Nectin细胞黏附分子4的抗体偶联药物。此外，公司已建立包括13个以上不同品种的药物资产的管线产品组合。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621060571","title":"邁威生物(688062.SH)發布2025年度業績，歸母淨虧損9.69億","url":"https://stock-news.laohu8.com/highlight/detail?id=2621060571","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621060571?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 21:13","pubTimestamp":1774358034,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布2025年年度报告，报告期内，公司实现营业收入6.63亿元，同比增长231.62%。归属于上市公司股东的净亏损9.69亿元，归属于上市公司股东的扣除非经常性损益的净亏损9.99亿元，基本每股亏损2.43元。报告期归属于上市公司股东的净亏损较上年同期减少7,458.56万元，归属于上市公司股东的扣除非经常性损益的净亏损较上年同期减少7,075.02万元，主要系公司与齐鲁制药、DISC的授权许可合同确认收入金额较大，同时药品销售收入增加较多。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"迈威生物(688062.SH)发布2025年度业绩，归母净亏损9.69亿","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607771149","title":"超10家赴港排隊上市，「A+H」成醫藥IPO新選擇，A股藥企為何集體奔赴港股？","url":"https://stock-news.laohu8.com/highlight/detail?id=2607771149","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607771149?lang=zh_tw&edition=fundamental","pubTime":"2026-01-29 12:11","pubTimestamp":1769659860,"startTime":"0","endTime":"0","summary":"　　又有药企冲刺港交所。　　近日，登陆科创板四年的迪哲医药宣布提交港股上市申请，成为2025年以来第14家宣布赴港上市的内地上市药企。自2024年4月以来，证监会发文明确支持龙头企业赴港上市后，港交所又相继宣布A股公司申请赴港上市可快速审批，并推出了服务于特专科技公司及生物科技公司的“科企专线”，进一步便利内地企业跨境上市。　　港交所披露易显示，截至2025年底，排队等待上市的企业数量达到316家。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-01-29/doc-inhixyye5302254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK1515","159938","159982","399300","BK1574","09939","BK4588","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}